医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mo[+] Plus: Composite Product for Hair Care by Mirae Wellcare

2023年10月25日 PM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Mirae Wellcare, a South Korean health food provider, introduces Mo[+] Plus, a hair care composite product that promotes healthy hair.

It is created by combining six key ingredients with hair loss management effects in a golden ratio, including brewer’s yeast, biotin, roasted seaweed powder, houttuynia cordata, black ginseng powder, and kelp extract powder, as well as premium ingredients that have been recognized by the South Korean Ministry of Food and Drug Safety for their functionality. Biotin, in particular, is an essential nutrient for hair strengthening, organization, and production.

Prior to the manufacturing process, all raw materials of Mo[+] Plus are subject to metal contamination and E. coli testing. In appreciation of its safe production procedure, the product acquired HACCP accreditation, a food safety management certification.

Mo[+] Plus is made from natural materials without adverse effects and may be taken with other medications. It is suitable for both adult males and females. It should be taken twice a day, with two tablets each time. Mo[+] Plus is prepared in the shape of a refined pill and is easy to take.

The National Health Service of South Korea estimates that approximately 10 million Koreans suffer from hair loss. In particular, the number of young hair loss sufferers is growing in Korea, with the Health Insurance Review and Assessment Service reporting that patients with alopecia areata reached 160,000 in 2016, of which 70,000 were in their 20s and 30s, accounting for nearly half of the total proportion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231025042531/en/

CONTACT

EDL ENTERPRISE for Mirae Wellcare

Sujin Lee

lsj@edl.co.kr

同じカテゴリーの記事 

  • Heuron Gets FDA Green Light for Stroke Triage and Notification Solution
  • iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases
  • Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
  • Immunis Partners with Japanese Drug Company Toray to Reverse Sarcopenia
  • Otsuka to Terminate Development of AVP-786